M&A / Acquisition · Africa · Announced 17 Mar 2026

Sandoz → Strides Pharma

Strides Pharma agreed to acquire and in-license a portfolio of Sandoz branded generics across Sub-Saharan Africa for an initial US$12 million, saying the deal more than doubles its presence in the region.

Parties: Sandoz (Switzerland) → Strides Pharma (India)

Value
$12m
Territory
Release lists "Western Sahara (covering 10 countries)", Ghana, Nigeria and Kenya; the 10 countries are not named
Therapeutic area
Multi-therapy
Assets
Branded generics portfolio (anti-infective); Branded generics portfolio (cardiovascular); Branded generics portfolio (dermatology)
Announced
17 Mar 2026

Our analysis

Why this matters

On 17 March 2026, India's Strides Pharma Science announced that its subsidiary Strides Pharma International AG had entered into definitive agreements with Sandoz AG and its group entities to acquire and in-license a portfolio of branded generics across Sub-Saharan Africa. Some brands are fully acquired; others Strides will continue to market on Sandoz's behalf. The brands span anti-infective, cardiovascular and dermatology segments, and several individually sell more than US$1 million a year. The initial consideration is US$12 million, payable at closing and funded from internal accruals. Closing was expected by the end of September 2026, subject to regulatory and antitrust approvals.

Strides says the deal more than doubles its regional presence and should place it among the top five pharmaceutical companies in Sub-Saharan Africa by sales. A separate manufacturing and supply agreement keeps Sandoz producing the brands.

The full analysis is free to read with a work email on this page.

Source: Strides Pharma Science press release; BioSpectrum India

More deals involving Sandoz or Strides Pharma

Latest deals

All Africa deals → · All m&a / acquisition deals → · Browse all emerging-market pharma deals →